Ladenburg Thalmann Downgrades Intra-Cellular Therapies (ITCI) to Neutral
Tweet Send to a Friend
Ladenburg Thalmann downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Buy to Neutral, removes $36.00 price target.Analyst Dr. Chris James is encouraged ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
